[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 23 of about 23
3. Rodriguez FJ, Scheithauer BW, Erickson LA, Jenkins RB, Giannini C: Ectopic low-grade adrenocortical carcinoma in the spinal region: immunohistochemical and molecular cytogenetic study of a pediatric case. Am J Surg Pathol; 2009 Jan;33(1):142-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ectopic low-grade adrenocortical carcinoma in the spinal region: immunohistochemical and molecular cytogenetic study of a pediatric case.
  • This report demonstrates that ectopic adrenocortical tumors in the nervous system may exhibit clinicopathologic and cytogenetic features suggestive of adrenocortical carcinoma.

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 1999 Dec;112(6):801-9 [10587703.001]
  • [Cites] Neurosurgery. 2006 Nov;59(5):E1144; discussion E1144 [17143207.001]
  • [Cites] Endocr Pathol. 2001 Winter;12(4):429-35 [11949624.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jul;87(7):3467-74 [12107267.001]
  • [Cites] ANZ J Surg. 2003 Sep;73(9):727-38 [12956790.001]
  • [Cites] Int J Surg Pathol. 2004 Jul;12(3):259-64 [15306940.001]
  • [Cites] J Clin Endocrinol Metab. 1971 Feb;32(2):201-10 [4321503.001]
  • [Cites] Am J Med. 1981 May;70(5):1122-5 [7234878.001]
  • [Cites] Am J Surg Pathol. 1990 May;14(5):481-4 [2327553.001]
  • [Cites] Neurosurgery. 1993 Apr;32(4):658-61; discussion 661-2 [8474656.001]
  • [Cites] Virchows Arch. 1996 Mar;427(6):613-7 [8605573.001]
  • [Cites] Cancer Res. 1996 Sep 15;56(18):4219-23 [8797595.001]
  • [Cites] Neurosurgery. 1998 Mar;42(3):650-4 [9527001.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Aug;84(8):2776-9 [10443678.001]
  • [Cites] AMA Arch Pathol. 1959 Feb;67(2):228-33 [13616833.001]
  • [Cites] J Neurooncol. 2005 Nov;75(2):127-33 [16132517.001]
  • [Cites] Eur J Endocrinol. 2006 Apr;154(4):587-98 [16556722.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6762-7 [11559548.001]
  • (PMID = 18941403.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / T32 NS007494; United States / NINDS NIH HHS / NS / T32 NS07494-04
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS396174; NLM/ PMC3427599
  •  go-up   go-down


Advertisement
4. Saito S, Ito K, Suzuki T, Utsunomiya H, Akahira J, Sugihashi Y, Niikura H, Okamura K, Yaegashi N, Sasano H: Orphan nuclear receptor DAX-1 in human endometrium and its disorders. Cancer Sci; 2005 Oct;96(10):645-52

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DAX-1 (dosage-sensitive sex reversal adrenal hypoplasia congenita critical region on the X chromosome gene 1) is a recently characterized member of the orphan nuclear receptor family.
  • It inhibits adrenal 4 binding protein (Ad4BP)/steroidogenic factor-1 (SF-1) pathway-dependent P450arom expression in cultured human endometriotic stromal cells and acts as a corepressor for estrogen receptors (ER).
  • In this study we first examined the localization of DAX-1 in 46 normal cycling endometria, 36 cases of endometrial hyperplasia and 103 cases of endometrial carcinoma by using immunohistochemistry to elucidate the possible involvement of DAX-1 and its correlation to the status of Ad4BP/SF-1, a universal transcription factor of steroidogenesis.
  • We then evaluated DAX-1 mRNA expression, using quantitative reverse transcription-polymerase chain reaction for DAX-1 in 33 cases of endometrial carcinoma for further characterization.
  • A significant inverse correlation was detected between the status of DAX-1 immunoreactivity and histological grade (P = 0.0003) in endometrial carcinoma.
  • The labeling index (LI) values of DAX-1 in normal endometrium during the secretory phase (P < 0.0001) and hyperplasia (P < 0.0001) were significantly higher than that of carcinoma.
  • These findings suggest that DAX-1 may inhibit the proliferation and progression of endometrial carcinoma through inhibition of estrogenic actions, possibly by interacting with ER present in carcinoma cells, rather than regulating in situ steroidogenesis.
  • [MeSH-major] Carcinoma / physiopathology. DNA-Binding Proteins / analysis. DNA-Binding Proteins / physiology. Endometrial Neoplasms / physiopathology. Endometrium / chemistry. Receptors, Retinoic Acid / analysis. Receptors, Retinoic Acid / physiology. Repressor Proteins / analysis. Repressor Proteins / physiology
  • [MeSH-minor] Adrenal Glands / cytology. Aromatase / biosynthesis. Cell Line. DAX-1 Orphan Nuclear Receptor. Endometrial Hyperplasia / physiopathology. Estrogen Receptor alpha. Estrogen Receptor beta. Female. HeLa Cells. Humans. Immunohistochemistry. RNA, Messenger / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16232195.001).
  • [ISSN] 1347-9032
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DAX-1 Orphan Nuclear Receptor; 0 / DNA-Binding Proteins; 0 / Estrogen Receptor alpha; 0 / Estrogen Receptor beta; 0 / NR0B1 protein, human; 0 / RNA, Messenger; 0 / Receptors, Retinoic Acid; 0 / Repressor Proteins; EC 1.14.14.1 / Aromatase
  •  go-up   go-down


5. Daniele L, Cassoni P, Bacillo E, Cappia S, Righi L, Volante M, Tondat F, Inghirami G, Sapino A, Scagliotti GV, Papotti M, Novello S: Epidermal growth factor receptor gene in primary tumor and metastatic sites from non-small cell lung cancer. J Thorac Oncol; 2009 Jun;4(6):684-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors are capable of reducing brain and adrenal metastases.
  • METHODS: Using fluorescence in situ hybridization (FISH) analysis, the EGFR gene status was evaluated in a series of 38 cerebral or adrenal metastases collected from two institutions and in the corresponding primary tumors.
  • Among the seven cases FISH-positive at the metastatic site but negative in the primary tumor, six were brain metastases, and one was an adrenal metastasis; all were polysomic for chromosome 7, none were amplified.
  • CONCLUSION: Because the molecular asset of EGFR may change during the metastatic progression of NSCLC to brain (but not to adrenal), the selection of patients with brain metastasis for specific targeted therapies by EGFR FISH analysis should be performed on metastatic lesions rather than on their corresponding primary tumors.
  • [MeSH-major] Adrenal Gland Neoplasms / genetics. Brain Neoplasms / genetics. Carcinoma, Non-Small-Cell Lung / genetics. Lung Neoplasms / genetics. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / secondary. Aged. Aged, 80 and over. Carcinoma, Large Cell / genetics. Carcinoma, Large Cell / secondary. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / secondary. Chromosomes, Human, Pair 7 / genetics. DNA, Neoplasm / genetics. DNA, Neoplasm / metabolism. Female. Gene Expression Regulation, Neoplastic. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Prognosis. Small Cell Lung Carcinoma / genetics. Small Cell Lung Carcinoma / secondary. Survival Rate


6. Sasano H, Miki Y, Nagasaki S, Suzuki T: In situ estrogen production and its regulation in human breast carcinoma: from endocrinology to intracrinology. Pathol Int; 2009 Nov;59(11):777-89
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In situ estrogen production and its regulation in human breast carcinoma: from endocrinology to intracrinology.
  • The great majority of breast carcinomas arising in postmenopausal women are estrogen dependent or positive for estrogen receptor (ER) in carcinoma cells despite markedly low plasma or circulating estrogen concentrations.
  • In these patients, biologically active estrogens are locally produced from circulating inactive steroids including adrenal androgens in an intracrine mechanism in the breast cancer tissues and confer estrogenic activities on carcinoma cells.
  • A series of enzymes are involved in this intra-tumoral or in situ production of estrogens in breast carcinoma tissues but aromatase, a member of the cytochrome P450 family, is a key enzyme of estrogen production through conversion from circulating adrenal androgens in estrogen-dependent postmenopausal breast cancer.
  • There has been, however, controversy regarding intra-tumoral localization of aromatase in breast carcinoma, especially whether intra-tumoral production of estrogens through aromatase occurs in carcinoma or stromal cells.
  • The enzyme was demonstrated to be expressed in both carcinoma and stromal cells in breast carcinoma tissues on immunohistochemistry with a well-characterized mAb 677 and combined laser capture microdissection/qualitative reverse transcriptase-polymerase chain reaction.
  • Intra-tumoral aromatase in both of these cell types was subsequently demonstrated to be induced by carcinoma-stromal interactions associated with carcinoma invasion in breast tissue.
  • The signals through various nuclear receptors, especially estrogen-related receptor-alpha in carcinoma cells and liver receptor homologue-1 in adipocytes adjacent to carcinoma invasion, in conjunction with various cytokines and/or growth factors, play pivotal roles in this induction of intra-tumoral aromatase.
  • This increased aromatase subsequently results in increased in situ estrogen concentrations of breast cancer.
  • Aromatase inhibitors are currently established as the gold standard for the treatment for ER-positive breast carcinoma but resistance to the therapy still remains to be solved by other modes of suppression of intra-tumoral estrogen production.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19883428.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Estrogens; EC 1.14.14.1 / Aromatase
  • [Number-of-references] 102
  •  go-up   go-down


7. van Nederveen FH, de Krijger RR: Precursor lesions of the adrenal gland. Pathobiology; 2007;74(5):285-90
MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Precursor lesions of the adrenal gland.
  • RESULTS: In the adrenal cortex hyperplasia and adenomas are frequently observed tumours or tumour-like conditions.
  • Although extensive follow-up studies might argue against multistep carcinogenesis, analysis of chromosomal imbalances and gene expression profiling studies in these tumours are inconclusive and could give support for both multistep pathogenesis or de novo genesis of carcinomas.
  • In the adrenal medulla, pheochromocytomas (PCC) are the most frequent tumours in adults, with an incidence of 8 per million.
  • Arbitrarily, lesions of less than 1 cm in diameter are called hyperplastic, but it should be expected that the majority of these are early lesions and if left in situ would grow to classify as PCC.
  • [MeSH-major] Adenoma / pathology. Adrenal Gland Neoplasms / pathology. Carcinoma / pathology. Precancerous Conditions / pathology
  • [MeSH-minor] Adrenal Cortex / pathology. Adrenal Cortex / physiology. Adrenal Medulla / pathology. Adrenal Medulla / physiology. Disease Progression. Humans. Hyperplasia / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 S. Karger AG, Basel.
  • (PMID = 17890895.001).
  • [ISSN] 1423-0291
  • [Journal-full-title] Pathobiology : journal of immunopathology, molecular and cellular biology
  • [ISO-abbreviation] Pathobiology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 44
  •  go-up   go-down


8. Alamdari FI, Ljungberg B: Adrenal metastasis in renal cell carcinoma: a recommendation for adjustment of the TNM staging system. Scand J Urol Nephrol; 2005;39(4):277-82
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenal metastasis in renal cell carcinoma: a recommendation for adjustment of the TNM staging system.
  • OBJECTIVES: To study the incidence of adrenal metastasis in patients with renal cell carcinoma (RCC) of all stages, its correlation with clinicopathological variables and its impact on survival.
  • The accuracy of the available preoperative radiological examinations was evaluated and any adrenal involvement was compared with other clinical and histopathological findings.
  • RESULTS: Ipsilateral adrenal tumour involvement was detected in 17/321 patients (5.3%).
  • In four of these patients, the adrenal gland was the only preoperatively found metastatic site.
  • Factors predicting the presence of ipsilateral adrenal metastases were male gender, tumour size, vein invasion, renal capsule and perirenal fat invasion.
  • Tumour location within the kidney and tumour side had no predictive value for the presence of adrenal metastasis.
  • The presence of ipsilateral adrenal involvement was a significant adverse prognostic variable, indicating a short survival time (p<0.001).
  • CONCLUSIONS: Ipsilateral adrenal metastasis is a highly adverse prognostic factor.
  • In the TNM staging system, adrenal gland involvement should be staged as M1a.
  • Ipsilateral adrenalectomy in conjunction with radical nephrectomy should be performed if an adrenal lesion cannot be cleared of suspicion after preoperative radiological imaging, as in locally advanced tumours.
  • The adrenal gland can be left in situ if the ipsilateral adrenal gland is assessed as normal at the preoperative investigation and perioperatively by the surgeon.
  • [MeSH-major] Adrenal Gland Neoplasms / secondary. Carcinoma, Renal Cell / secondary. Kidney Neoplasms / pathology

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16118103.001).
  • [ISSN] 0036-5599
  • [Journal-full-title] Scandinavian journal of urology and nephrology
  • [ISO-abbreviation] Scand. J. Urol. Nephrol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Sweden
  •  go-up   go-down


9. Toti P, Regoli M, Nesi G, Occhini R, Bartolommei S, Fonzi L, Bertelli E: Nestin expression in normal adrenal gland and adrenocortical tumors. Histol Histopathol; 2005 10;20(4):1115-20
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nestin expression in normal adrenal gland and adrenocortical tumors.
  • Nestin is an intermediate filament protein that is mainly expressed in the developing nervous system and that has been recently reported in rat adrenal gland as well.
  • Using immunohistochemical and biochemical approaches, the present study demonstrates that nestin is constantly expressed in situ in the cortex of normal human adrenal glands.
  • In contrast, adrenal carcinomas displayed a variable number of nestin-immunoreactive cells that in some cases were virtually absent.
  • Samples of renal clear cell carcinoma metastasis in the adrenals were also examined which did not show nestin-immunoreactivity.
  • We propose that a positive nestin-immunoreaction could be useful in differential diagnosis of clear cell tumors in adrenal glands.
  • [MeSH-major] Adrenal Cortex Neoplasms / metabolism. Adrenal Glands / metabolism. Adrenal Glands / pathology. Intermediate Filament Proteins / biosynthesis. Nerve Tissue Proteins / biosynthesis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16136494.001).
  • [ISSN] 0213-3911
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nes protein, rat; 0 / Nestin
  •  go-up   go-down


10. Raynaud CM, Mercier O, Commo F, Dartevelle P, Gomez-Roca C, de Montpreville V, Sabatier L, Soria JC: Telomere length, telomeric proteins and DNA damage repair proteins are differentially expressed between primary lung tumors and their adrenal metastases. Lung Cancer; 2009 Aug;65(2):144-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Telomere length, telomeric proteins and DNA damage repair proteins are differentially expressed between primary lung tumors and their adrenal metastases.
  • We analysed telomere related markers (telomere length and telomeric proteins) and DNA damage repair (DDR) markers in a cohort of patients with surgically resected primary lung NSCLC and adrenal metastasis.
  • MATERIAL AND METHODS: We studied a single series of 21 patients who had undergone surgery of both their primary lung tumor and its related adrenal gland metastasis in a single Institution.
  • DDR and telomeric proteins were analysed by immunohistochemistry and telomere length was assessed by fluorescent in situ hybridization in 17 paired samples.
  • Cluster analysis of each specimen according to its protein's expression levels and telomere length showed that matched primary tumors/adrenal metastasis were mostly separated into different clusters.
  • [MeSH-major] Adrenal Gland Neoplasms / metabolism. Biomarkers, Tumor / analysis. DNA Repair / physiology. DNA Repair Enzymes / metabolism. Lung Neoplasms / metabolism. Telomere / metabolism
  • [MeSH-minor] Adult. Aged. Carcinoma, Non-Small-Cell Lung / genetics. Carcinoma, Non-Small-Cell Lung / secondary. Cluster Analysis. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19091442.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down


11. Stewart JW, Koehler K, Jackson W, Hawley J, Wang W, Au A, Myers R, Birt DF: Prevention of mouse skin tumor promotion by dietary energy restriction requires an intact adrenal gland and glucocorticoid supplementation restores inhibition. Carcinogenesis; 2005 Jun;26(6):1077-84
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevention of mouse skin tumor promotion by dietary energy restriction requires an intact adrenal gland and glucocorticoid supplementation restores inhibition.
  • The purpose of the research reported here was to determine if circulating corticosterone (CCS) may be the adrenal hormone responsible for DER prevention of skin carcinogenesis.
  • CCS, the main glucocorticoid hormone secreted by the murine adrenal gland, was added to the drinking water of AL/ADX and DER/ADX groups to determine the role of CCS in the DER inhibition of tumor development.
  • DER significantly reduced carcinoma multiplicity mean counts per effective animal (P < 0.0001) compared with AL-fed groups in sham and ADX/CCS groups.
  • DER/ADX mice lost the carcinoma multiplicity protection seen in sham/DER mice.
  • CCS treatment of ADX mice significantly decreased total carcinoma (in situ and invasive) incidence rates per effective animal (P < 0.0003).
  • ADX followed by CCS treatment in the DER mice resulted in the lowest carcinoma incidence and multiplicity.
  • [MeSH-major] Adrenal Glands / metabolism. Carcinoma / prevention & control. Corticosterone / metabolism. Diet, Fat-Restricted. Dietary Carbohydrates / administration & dosage. Papilloma / prevention & control. Skin Neoplasms / prevention & control

  • MedlinePlus Health Information. consumer health - Carbohydrates.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15746164.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA77451
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Benz(a)Anthracenes; 0 / Dietary Carbohydrates; 2564-65-0 / 7,12-dihydroxymethylbenz(a)anthracene; 67763-96-6 / Insulin-Like Growth Factor I; W980KJ009P / Corticosterone
  •  go-up   go-down


12. Viterbo R, Greenberg RE, Al-Saleem T, Uzzo RG: Prior abdominal surgery and radiation do not complicate the retroperitoneoscopic approach to the kidney or adrenal gland. J Urol; 2005 Aug;174(2):446-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prior abdominal surgery and radiation do not complicate the retroperitoneoscopic approach to the kidney or adrenal gland.
  • PURPOSE: Laparoscopic renal and adrenal surgery is an accepted standard of care.
  • MATERIALS AND METHODS: We evaluated clinical and functional parameters in 78 consecutive patients undergoing retroperitoneoscopic renal or adrenal surgery performed by a single surgeon in a 36-month period, including radical nephrectomy with or without ureterectomy in 50, nerve sparing surgery in 8, ablation in 16 and adrenalectomy in 4.
  • Pathological findings showed malignancy in 57 cases (renal cell carcinoma, transitional cell carcinoma, carcinoid disease and metastases) and benign disease in 21 (oncocytoma, adenoma, pyelonephritis and complex cysts).
  • All margins were negative except in 1 group patient with carcinoma in situ at the bladder cuff margin.
  • CONCLUSIONS: The retroperitoneoscopic approach to the kidney and adrenal glands can be used in patients with extensive prior open abdominal surgery and/or radiation without significant increases in morbidity or convalescence.
  • [MeSH-major] Adrenal Gland Neoplasms / surgery. Adrenalectomy / methods. Kidney Neoplasms / surgery. Laparoscopy / methods. Nephrectomy / methods

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16006862.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Shehata BM, Steelman CK, Abramowsky CR, Olson TA, French CA, Saxe DF, Ricketts RR, Katzenstein HM: NUT midline carcinoma in a newborn with multiorgan disseminated tumor and a 2-year-old with a pancreatic/hepatic primary. Pediatr Dev Pathol; 2010 Nov-Dec;13(6):481-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NUT midline carcinoma in a newborn with multiorgan disseminated tumor and a 2-year-old with a pancreatic/hepatic primary.
  • NUT midline carcinoma (NMC) is a rare and aggressive malignant epithelial tumor defined by rearrangement of the NUT gene on chromosome 15.
  • The 1st case involves a newborn who presented with a supraorbital mass and extensive multiorgan involvement, including the spine, lungs, liver, pancreas, adrenal glands, and subcutaneous tissue.
  • Both tumors demonstrated t(15;19), and immunohistochemistry with NUT monoclonal antibodies and fluorescent in situ hybridization confirmed NUT rearrangement.
  • [MeSH-major] Carcinoma / pathology. Liver Neoplasms / pathology. Nuclear Proteins / genetics. Oncogene Proteins / genetics. Orbital Neoplasms / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20017639.001).
  • [ISSN] 1093-5266
  • [Journal-full-title] Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
  • [ISO-abbreviation] Pediatr. Dev. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BRD4 protein, human; 0 / BRD4-NUT fusion oncogene protein, human; 0 / NUT protein, human; 0 / Nuclear Proteins; 0 / Oncogene Proteins; 0 / Oncogene Proteins, Fusion; 0 / Transcription Factors
  •  go-up   go-down


15. Cassoni P, Daniele L, Maldi E, Righi L, Tavaglione V, Novello S, Volante M, Scagliotti GV, Papotti M: Caveolin-1 expression in lung carcinoma varies according to tumour histotype and is acquired de novo in brain metastases. Histopathology; 2009 Jul;55(1):20-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Caveolin-1 expression in lung carcinoma varies according to tumour histotype and is acquired de novo in brain metastases.
  • In 34 tumours metastatic to the brain, primary and secondary lesions were compared and 53% of brain metastases were Cav-1+ vs. 20.6% of primaries, indicating a de novo acquisition of Cav-1 expression.
  • This pattern was exclusive to the brain, as it was not acquired in adrenal metastases.
  • In our series, the presence of epidermal growth factor receptor amplification, determined by fluorescence in situ hybridization, was not related to Cav-1 reactivity.
  • CONCLUSIONS: Cav-1 immunoreactivity in lung carcinoma is histotype-dependent and acquired de novo in brain metastases, suggesting a site-specific phenotypic shift in secondary lesions.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Brain Neoplasms / metabolism. Carcinoma, Large Cell / metabolism. Carcinoma, Squamous Cell / metabolism. Caveolin 1 / metabolism. Lung Neoplasms / metabolism
  • [MeSH-minor] Adrenal Gland Neoplasms / metabolism. Adrenal Gland Neoplasms / secondary. DNA, Neoplasm / genetics. Disease Progression. Gene Amplification / genetics. Gene Expression Regulation, Neoplastic. Humans. Receptor, Epidermal Growth Factor / genetics. Receptor, Epidermal Growth Factor / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19614763.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Caveolin 1; 0 / DNA, Neoplasm; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


16. Reiter R, Brosch S: [Chronic laryngitis--associated factors and voice assessment]. Laryngorhinootologie; 2009 Mar;88(3):181-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Chronic laryngitis may be a predisposing factor for laryngeal carcinoma.
  • On histological examination one of them had a high grade dysplasia and two of them had a carcinoma in situ.
  • [MeSH-minor] Administration, Inhalation. Adrenal Cortex Hormones / administration & dosage. Adrenal Cortex Hormones / adverse effects. Adult. Aged. Aged, 80 and over. Alcohol Drinking / adverse effects. Biopsy. Carcinoma in Situ / etiology. Carcinoma in Situ / pathology. Carcinoma in Situ / psychology. Chronic Disease. Female. Gastroesophageal Reflux / complications. Gastroesophageal Reflux / pathology. Gastroesophageal Reflux / psychology. Hoarseness / etiology. Humans. Laryngeal Neoplasms / etiology. Laryngeal Neoplasms / pathology. Laryngeal Neoplasms / psychology. Laryngoscopy. Leukoplakia / etiology. Leukoplakia / pathology. Leukoplakia / psychology. Male. Middle Aged. Precancerous Conditions / etiology. Precancerous Conditions / pathology. Precancerous Conditions / psychology. Smoking / adverse effects. Vocal Cords / pathology. Voice Disorders / diagnosis. Voice Disorders / psychology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19037841.001).
  • [ISSN] 0935-8943
  • [Journal-full-title] Laryngo- rhino- otologie
  • [ISO-abbreviation] Laryngorhinootologie
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones
  •  go-up   go-down


17. Campagnacci R, Guerrieri M, De Sanctis A, Sarnari J, Lezoche E: Laparoscopic radiofrequency renal ablation in patients with simultaneous visceral tumors: long-term follow-up. J Endourol; 2006 May;20(5):321-5
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To report our experience with in situ laparoscopic radiofrequency ablation (RFA) of renal tumors.
  • PATIENTS AND METHODS: From September 2000 to May 2002, two men, 81 and 71 years old, and one woman, 75 years old, were referred to our department for right renal clear-cell carcinoma <3.5-cm diameter.
  • Moreover, a simultaneous large right adrenal incidentaloma (myelolipoma) and a right colon cancer were known to be present in the second and third patient, respectively.

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16724903.001).
  • [ISSN] 0892-7790
  • [Journal-full-title] Journal of endourology
  • [ISO-abbreviation] J. Endourol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Todd RW, Luesley DM: Medical management of vulvar intraepithelial neoplasia. J Low Genit Tract Dis; 2005 Oct;9(4):206-12
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Carcinoma in Situ / drug therapy. Vulvar Neoplasms / drug therapy
  • [MeSH-minor] Adrenal Cortex Hormones / therapeutic use. Antineoplastic Agents / therapeutic use. Female. Humans. Photochemotherapy. Retinoids / therapeutic use. Treatment Outcome. Vaccination

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16205189.001).
  • [ISSN] 1089-2591
  • [Journal-full-title] Journal of lower genital tract disease
  • [ISO-abbreviation] J Low Genit Tract Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Antineoplastic Agents; 0 / Retinoids
  • [Number-of-references] 40
  •  go-up   go-down


19. Willenberg HS, Haase M, Papewalis C, Schott M, Scherbaum WA, Bornstein SR: Corticotropin-releasing hormone receptor expression on normal and tumorous human adrenocortical cells. Neuroendocrinology; 2005;82(5-6):274-81
MedlinePlus Health Information. consumer health - Pheochromocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Corticotropin-releasing hormone (CRH) is not only the principal regulator of the central hypothalamic-pituitary-adrenal (HPA) axis but also exerts direct actions on peripheral tissues.
  • We analyzed the expression of CRH receptors in microdissected preparations of normal human adrenal glands and in adrenocortical and adrenomedullary tumors, employing immunohistochemistry, quantitative RT-PCR of microdissected adrenal tissues, and in situ hybridization.
  • The effect of CRH on adrenal steroidogenesis was tested in adrenal cells.
  • In addition, we found a higher expression of CRH type-1 and 2 receptors mRNAs in preparations of adrenal cortices as compared to pheochromocytomas, a 6-fold increase in preparations of clinically unapparent adrenocortical adenomas, and a 10- to 60-fold increase in cortisol-producing adrenal adenomas.
  • Stimulation of the adrenal tumor cell line NCI-H295R with CRH elicited a 1.4-fold increase in DHEA secretion.
  • We conclude that adrenocortical cells exhibit a higher expression of functional CRH receptors than chromaffin cells and that CRH acts on adrenal DHEA production.
  • The data support the assertion of a direct action of CRH on human adrenocortical cells in addition to an intra-adrenal CRH receptor/adrenocorticotropin system.
  • [MeSH-major] Adrenal Cortex / chemistry. Adrenal Cortex Neoplasms / chemistry. Adrenocortical Adenoma / chemistry. Adrenocortical Carcinoma / chemistry. Pheochromocytoma / chemistry. Receptors, Corticotropin-Releasing Hormone / genetics
  • [MeSH-minor] Corticotropin-Releasing Hormone / pharmacology. Gene Expression Regulation. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. In Situ Hybridization. Microdissection / methods. RNA, Messenger / analysis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16721033.001).
  • [ISSN] 0028-3835
  • [Journal-full-title] Neuroendocrinology
  • [ISO-abbreviation] Neuroendocrinology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / CRF receptor type 1; 0 / CRF receptor type 2; 0 / RNA, Messenger; 0 / Receptors, Corticotropin-Releasing Hormone; 9015-71-8 / Corticotropin-Releasing Hormone
  •  go-up   go-down


20. Las Heras F, Pritzker KP, Colgan TJ: Chordoma arising in a mature cystic teratoma of the ovary: a case report. Pathol Res Pract; 2007;203(6):467-71
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Unusual types of tissues can be found in MCTO, such as kidney, adrenal, and prostatic tissues.
  • Squamous cell carcinoma is the most common malignancy arising in these otherwise benign tumors.
  • The chordoma differentiation was supported by immunohistochemical staining and interphase fluorescence in situ hybridization (IP-FISH) technique showing 19% of the nuclei of the MCTO displaying polysomy for the chromosome X, while 28% of the chordoma nuclei showed chromosome 7 mosaicism.
  • [MeSH-major] Cell Differentiation. Cell Transformation, Neoplastic / pathology. Chordoma / diagnosis. Ovarian Neoplasms / diagnosis. Teratoma / diagnosis
  • [MeSH-minor] Adult. Chromosomes, Human, Pair 7. Chromosomes, Human, X. Diagnosis, Differential. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Keratins / analysis. Ki-67 Antigen / analysis. Mosaicism. Mucin-1 / analysis. S100 Proteins / analysis. Tumor Suppressor Protein p53 / analysis. Vimentin / analysis

  • Genetic Alliance. consumer health - Chordoma.
  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17418959.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Mucin-1; 0 / S100 Proteins; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; 0 / Vimentin; 68238-35-7 / Keratins
  •  go-up   go-down


21. Shilkaitis A, Green A, Punj V, Steele V, Lubet R, Christov K: Dehydroepiandrosterone inhibits the progression phase of mammary carcinogenesis by inducing cellular senescence via a p16-dependent but p53-independent mechanism. Breast Cancer Res; 2005;7(6):R1132-40
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Dehydroepiandrosterone (DHEA), an adrenal 17-ketosteroid, is a precursor of testosterone and 17beta-estradiol.
  • Studies have shown that DHEA inhibits carcinogenesis in mammary gland and prostate as well as other organs, a process that is not hormone dependent.
  • Here we examine whether DHEA and its analog DHEA 8354 can suppress the progression of hyperplastic and premalignant (carcinoma in situ) lesions in mammary gland toward malignant tumors and the cellular mechanisms involved.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. N-NITROSO-N-METHYLUREA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Carcinogenesis. 1999 Aug;20(8):1535-40 [10426803.001]
  • [Cites] Cancer Res. 1999 Jul 1;59(13):3084-9 [10397249.001]
  • [Cites] Oncogene. 1997 Nov 20;15(21):2589-96 [9399646.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4291-6 [10760295.001]
  • [Cites] Breast Cancer Res Treat. 2000 Mar;60(2):117-28 [10845274.001]
  • [Cites] J Natl Cancer Inst. 2001 Jan 3;93(1):39-45 [11136840.001]
  • [Cites] Front Neuroendocrinol. 2001 Jul;22(3):185-212 [11456468.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7449-55 [11606379.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1876-83 [11912168.001]
  • [Cites] Eur J Cancer. 2003 Jan;39(2):230-9 [12509956.001]
  • [Cites] Breast Cancer Res Treat. 2003 Feb;77(3):253-64 [12602925.001]
  • [Cites] Int J Oncol. 2004 Jun;24(6):1597-605 [15138605.001]
  • [Cites] Lancet. 1971 Aug 21;2(7721):395-8 [4105173.001]
  • [Cites] Cancer Res. 1980 Aug;40(8 Pt 1):2677-87 [7388818.001]
  • [Cites] Cancer Res. 1991 Jan 15;51(2):481-6 [1824682.001]
  • [Cites] Cytometry. 1990;11(7):753-70 [2272241.001]
  • [Cites] Breast Cancer Res Treat. 1994 Feb;29(2):203-17 [8012037.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9363-7 [7568133.001]
  • [Cites] Ann N Y Acad Sci. 1995 Dec 29;774:180-6 [8597458.001]
  • [Cites] Cancer Res. 1996 Apr 15;56(8):1724-6 [8620482.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Mar;6(3):177-81 [9138660.001]
  • [Cites] Breast Cancer Res Treat. 1997 Apr;43(2):105-15 [9131265.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Sep 2;94(18):9648-53 [9275177.001]
  • [Cites] Eur J Cancer. 1997 Apr;33(5):703-9 [9282108.001]
  • [Cites] Cancer Res. 1998 Mar 1;58(5):921-6 [9500451.001]
  • [Cites] J Natl Cancer Inst. 1998 May 20;90(10):772-8 [9605648.001]
  • [Cites] Cancer Res. 1999 Aug 1;59(15):3761-7 [10446993.001]
  • (PMID = 16457693.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CN / N01-CN-55179-MAO
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Alkylating Agents; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Tumor Suppressor Protein p53; 156680-74-9 / 5-androstene-16-fluoro-17-one; 459AG36T1B / Dehydroepiandrosterone; 684-93-5 / Methylnitrosourea
  • [Other-IDs] NLM/ PMC1410767
  •  go-up   go-down


22. Godoy A, Ulloa V, Rodríguez F, Reinicke K, Yañez AJ, García Mde L, Medina RA, Carrasco M, Barberis S, Castro T, Martínez F, Koch X, Vera JC, Poblete MT, Figueroa CD, Peruzzo B, Pérez F, Nualart F: Differential subcellular distribution of glucose transporters GLUT1-6 and GLUT9 in human cancer: ultrastructural localization of GLUT1 and GLUT5 in breast tumor tissues. J Cell Physiol; 2006 Jun;207(3):614-27
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • GLUT6 was principally detected in testis germinal cells and GLUT9 was localized in kidney, liver, heart, and adrenal.
  • GLUT2 was detected in 31% of the samples, being mainly expressed in breast, colon, and liver carcinoma.
  • GLUT5 was detected in 27% of breast and colon adenocarcinoma, liver carcinoma, lymphomas, and testis seminoma samples.
  • In situ RT-PCR and ultrastructural immunohistochemistry confirmed GLUT5 expression in breast cancer.
  • [MeSH-minor] Animals. Biopsy. Gene Expression Regulation, Neoplastic. Health. Humans. Immunohistochemistry. In Situ Hybridization. Mice. Microscopy, Immunoelectron. Organ Specificity. Rats. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16523487.001).
  • [ISSN] 0021-9541
  • [Journal-full-title] Journal of cellular physiology
  • [ISO-abbreviation] J. Cell. Physiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucose Transport Proteins, Facilitative
  •  go-up   go-down


23. Ghilardi C, Chiorino G, Dossi R, Nagy Z, Giavazzi R, Bani M: Identification of novel vascular markers through gene expression profiling of tumor-derived endothelium. BMC Genomics; 2008;9:201
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: We investigated by microarray analysis the gene expression profiles of EC purified and cultured from tumor (ovarian carcinoma [HOC-EC]) and normal (human adrenal gland [HA-EC]) tissue specimens.
  • In vivo investigation by in situ hybridization established that ADAM23, GPNMB and PRSS3 expression is localized on blood vessels of human cancer specimens.
  • [MeSH-minor] ADAM Proteins / genetics. Adrenal Glands / blood supply. Adrenal Glands / metabolism. Antigens, Neoplasm / genetics. Cell Line, Tumor. Female. Gelatinases. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Humans. Male. Membrane Glycoproteins / genetics. Membrane Proteins. Oligonucleotide Array Sequence Analysis. Ovarian Neoplasms / blood supply. Ovarian Neoplasms / genetics. Serine Endopeptidases / genetics. Trypsin / genetics

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proteomics. 2004 Jun;4(6):1737-60 [15174142.001]
  • [Cites] Biochim Biophys Acta. 2007 Jun;1775(2):237-62 [17572300.001]
  • [Cites] Nature. 2004 Jun 10;429(6992):629-35 [15190345.001]
  • [Cites] Am J Pathol. 2004 Aug;165(2):601-8 [15277233.001]
  • [Cites] J Clin Invest. 1973 Nov;52(11):2745-56 [4355998.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Sep;87(18):7235-9 [2402505.001]
  • [Cites] Microvasc Res. 1990 Sep;40(2):264-78 [1701206.001]
  • [Cites] Neurosci Lett. 1992 May 25;139(2):249-52 [1319017.001]
  • [Cites] J Pharmacol Exp Ther. 1993 Nov;267(2):951-60 [7504102.001]
  • [Cites] Science. 1994 Apr 22;264(5158):569-71 [7512751.001]
  • [Cites] Cell. 1994 Oct 21;79(2):315-28 [7525077.001]
  • [Cites] Nat Med. 1995 Jan;1(1):27-31 [7584949.001]
  • [Cites] Nature. 1996 Mar 28;380(6572):364-6 [8598934.001]
  • [Cites] J Biol Chem. 1997 Apr 18;272(16):10573-8 [9099703.001]
  • [Cites] Blood. 1997 Aug 1;90(3):1150-9 [9242547.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 1997 Jul;17(7):1193-202 [9261246.001]
  • [Cites] Lab Invest. 1998 Jan;78(1):127-8 [9461129.001]
  • [Cites] Biochem J. 1998 Aug 15;334 ( Pt 1):93-8 [9693107.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7857-66 [15520192.001]
  • [Cites] Oncogene. 2004 Nov 11;23(53):8705-10 [15467763.001]
  • [Cites] Mol Biol Cell. 2000 Apr;11(4):1457-69 [10749942.001]
  • [Cites] Microvasc Res. 2000 May;59(3):394-7 [10792972.001]
  • [Cites] Eur J Biochem. 2000 Jun;267(12):3567-74 [10848973.001]
  • [Cites] Am J Pathol. 2000 Jun;156(6):1887-900 [10854212.001]
  • [Cites] Exp Cell Res. 2000 Aug 1;258(2):384-94 [10896789.001]
  • [Cites] Clin Exp Metastasis. 1999;17(8):655-62 [10919710.001]
  • [Cites] Science. 2000 Aug 18;289(5482):1197-202 [10947988.001]
  • [Cites] Nature. 2000 Oct 12;407(6805):747-50 [11048721.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2183-8 [11280784.001]
  • [Cites] Am J Physiol Cell Physiol. 2002 May;282(5):C947-70 [11940508.001]
  • [Cites] Nucleic Acids Res. 2003 Jan 1;31(1):219-23 [12519986.001]
  • [Cites] J Neurochem. 2003 Jan;84(2):316-24 [12558994.001]
  • [Cites] Curr Opin Hematol. 2003 Mar;10(2):136-41 [12579040.001]
  • [Cites] J Cell Sci. 2003 Mar 15;116(Pt 6):1013-22 [12584245.001]
  • [Cites] Cornea. 2003 Mar;22(2):153-9 [12605052.001]
  • [Cites] Regul Pept. 2003 Mar 28;111(1-3):169-78 [12609765.001]
  • [Cites] Clin Cancer Res. 2003 May;9(5):1639-47 [12738716.001]
  • [Cites] Physiol Genomics. 2003 May 13;13(3):249-62 [12644598.001]
  • [Cites] J Pharmacol Exp Ther. 2003 Jul;306(1):8-12 [12660314.001]
  • [Cites] Eur J Cancer. 2003 Sep;39(13):1948-56 [12932675.001]
  • [Cites] Nat Rev Genet. 2003 Sep;4(9):710-20 [12951572.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10623-8 [12963823.001]
  • [Cites] J Biol Chem. 2003 Dec 5;278(49):48580-9 [14507909.001]
  • [Cites] Cancer Cell. 2003 Nov;4(5):383-91 [14667505.001]
  • [Cites] Mol Cancer Ther. 2004 Feb;3(2):111-21 [14985451.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Nov 16;101(46):16210-5 [15520390.001]
  • [Cites] Anticancer Res. 2005 Jan-Feb;25(1B):489-95 [15816617.001]
  • [Cites] Nat Methods. 2005 Apr;2(4):291-8 [15782212.001]
  • [Cites] Nat Rev Cancer. 2005 Jun;5(6):436-46 [15928674.001]
  • [Cites] Nature. 2005 Dec 15;438(7070):967-74 [16355214.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2006 Apr;26(4):716-28 [16469948.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4652-61 [16651416.001]
  • [Cites] Semin Reprod Med. 2006 Sep;24(4):270-82 [16944424.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11520-39 [17178843.001]
  • [Cites] Cancer Res. 2007 Feb 15;67(4):1757-68 [17308118.001]
  • [Cites] Thromb Haemost. 2007 Mar;97(3):336-42 [17334498.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2335-42 [15175435.001]
  • (PMID = 18447899.001).
  • [ISSN] 1471-2164
  • [Journal-full-title] BMC genomics
  • [ISO-abbreviation] BMC Genomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / GPNMB protein, human; 0 / Membrane Glycoproteins; 0 / Membrane Proteins; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.- / fibroblast activation protein alpha; EC 3.4.21.4 / PRSS3 protein, human; EC 3.4.21.4 / Trypsin; EC 3.4.24.- / ADAM Proteins; EC 3.4.24.- / ADAM23 protein, human; EC 3.4.24.- / Gelatinases
  • [Other-IDs] NLM/ PMC2410137
  •  go-up   go-down






Advertisement